



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
John P. CARULLI et al.)	Group Art Unit: 1636
Application No.: 10/731,739)	Examiner: Celine X. Qian, Ph.D.
Filed: December 10, 2003)	Confirmation No.: 5366
For: HIGH BONE MASS GENE OF 11q13.3)	

**REVOCATION AND NEW POWER OF ATTORNEY
AND CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under 37 C.F.R. § 3.73(b), Creighton University and Genome Therapeutics Corporation, U.S. entities, certify that they are the joint assignees of the right, title and interest in the issued patent application identified above, as reflected in the recorded Assignment of U.S. Application No. 09/544,398 (now U.S. Patent No 6,770,461) at Reel/Frame 010878/0010 on August 14, 2000. The instant application is a divisional application of U.S. Patent No. 6,770,461.

The undersigned have reviewed all documents in the chain of title of the patent application identified above and, to the best of the undersigned's knowledge and belief, title are in the assignees identified above.

The undersigned, whose titles are supplied below, are empowered to act on behalf of the respective assignees.

Acting on behalf of the assignee, the undersigned hereby revokes all powers of attorney previously granted in the patent application and appoint all of the attorneys listed at Customer Number 55694 with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected with this patent application and its progeny.

All correspondence regarding the patent should be sent to MERCEDES K.
MEYER at:

Customer Number 55694
DRINKER BIDDLE & REATH LLP
1500 K Street, N.W.
Suite 1100
Washington, D.C. 20005-1209

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the applications or any patents issued on the applications.

Respectfully submitted,

Date: _____

(Signature)
Name: Daniel E. Burkey
Title: Vice President, Administration
and Finance
CREIGHTON UNIVERSITY

Date: 23 OCTOBER 2006

(Signature)
Name: Dominick Colaagelo
Title: Executive VP Corporate Development Operations
GENOME THERAPEUTICS
CORPORATION